

Supporting Information

Direct construction of 2,3-unsubstituted benzofurans and benzothiophenes *via* metal-free catalyzed intramolecular Friedel-Crafts reaction

Weimin Ma[†], Jiawei Huang[†], Xianyu Huang, Shulin Meng, Zhengwei Yang, Chao Li, Yue Wang, Ting Qi, Baolin Li*


School of Chemical Sciences, University of Chinese Academy of Sciences, Beijing 100049, P. R. China

Table of contents

1. Screening of acids as the catalyst.....	S2
2. GC Standard curve of 2d	S3
3. Mechanism study for the synthesis of 2d by GC-MS.....	S4
4. General information.....	S6
5. General procedure A for the preparation of the starting materials.....	S7
6. General procedure B for the synthesis of benzofurans and benzothiophenes.....	S14
7. ¹ H and ¹³ C NMR spectra and HRMS spectra.....	S20
8. References.....	S90

1. Screening of acids as the catalyst

Table S1. Screening of acids as the catalyst^{a,b}



Entry	Catalyst	Solvent	T [°C]	GC yield ^b
1	H ₂ SO ₄	Toluene	110	trace
2	HNO ₃	Toluene	110	trace
3	HCl	Toluene	110	trace
4	CF ₃ COOH	Toluene	110	trace
5	CF ₃ SO ₃ H	Toluene	110	trace
6	TsOH	Toluene	110	trace
7	PPA ^c	Toluene	110	23%
8	BF ₃ -Et ₂ O	Toluene	110	trace
9	H ₃ PO ₄	Toluene	110	17%

^a Reaction conditions: unless otherwise noted, all reactions were performed with **1d** (1 mmol), catalyst (100 μ L) in 2.0 mL toluene at 110 °C for 12 h. ^b GC yield with TCE as internal standard. ^c 100 mg PPA was used.

2. GC Standard curve of 2d

Table S2. GC standard curve of 7-bromobenzofuran (**2d**) with TCE as internal reference.

GC Method: 50 °C hold for 1 min, followed by a temperature increase of 10 °C/min to 200 °C, and 30 °C/min to 300 °C, hold for 2 min (total run time: 21.3 min). Retention time: TCE 5.72 min, **2d** 12.1 min.

entry	Mass of 2d (mg)	Mass of TCE (mg)	$y = \frac{\text{Mass of } 2d}{\text{Mass of TCE}}$	Area of 2d	Area of TCE	$x = \frac{\text{Area of } 2d}{\text{Area of TCE}}$
1	0	0	0	0	0	0
2	9.2	32	0.2875	2358189	12180674	0.786918905
3	26.6	32	0.83125	7384301	9931586	2.221038125
4	41.2	32	1.2875	9433960	7151579	3.464410322
5	52.8	32	1.65	14638007	7461543	4.35185074
6	75.5	32	2.359375	20850021	8133414	6.427492562





Figure S1: The standard curve of **2d** with TCE.

3. Mechanism study for the synthesis of 2d

3.1 Mechanism study for the synthesis of 2d by GC-MS

Taking **2d** as an example, when the reaction mixture was stirred for 3 h at 130 °C, we took small amount of sample for testing, and the GC-MS spectra are shown below (Figure S2).

GC (TIC):



MS spectra:




Figure S2: GC-MS data of the reaction mixture for synthesis of **2d**.

3.2 Further verification of the proposed mechanism

To a 50 mL round-bottomed flask was added 1-bromo-2-(2,2-diethoxyethoxy)benzene (**1d**) (1.4 g, 5 mmol), phosphoric acid (1.5 ml, 4.8 equiv) and chlorobenzene (15 mL). The mixture was stirred at 80 °C for 3 h. Then the mixture was cooled to room temperature, the organic layer was separated and concentrated under reduced pressure. The residue was finally purified by flash silica gel column chromatography (eluting with petroleum ether/ethyl acetate) to afford the desired intermediate I: 2-(2-bromophenoxy)acetaldehyde (360 mg, 1.67 mmol, 33% yield) as yellow liquid. ¹H NMR (400 MHz, CDCl₃) δ 9.91 (s, 1H), 7.59 (dd, *J* = 7.9, 1.6 Hz, 1H), 7.29-7.25 (m, 1H), 6.92 (m, 1H), 6.79 (dd, *J* = 8.2, 1.3 Hz, 1H), 4.62 (s, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 199.04, 154.23, 133.99, 128.75, 123.40, 113.67, 112.44, 73.64. GC-MS (EI) *m/z* 214. IR: 3069, 2826, 2717 (ν_{C-H} of aldehyde group), 1731 (ν_{C=O}), 1586, 1442, 1282, 1240, 1055, 1028, 740, 657 cm⁻¹.

To a 10 mL Schleck tube was added 2-(2-bromophenoxy)acetaldehyde (108 mg, 0.5 mmol) isolated above, phosphoric acid (150 μL, 4.8 equiv) and chlorobenzene (1.5 mL). The mixture was stirred at 130 °C for 8 h. The GC yield is 90%. As we predicted, intermediate product I can be converted into the target product **2d** efficiently.


4. General information

All reagents were purchased from commercial suppliers and used without further purification unless otherwise specified. Thin layer chromatography (TLC) was performed using TLC silica gel 60 F254 glass plates. Silica gel 60 (200-300 mesh) was used for column chromatography. Proton nuclear magnetic resonance (^1H NMR) and carbon nuclear magnetic resonance (^{13}C NMR) spectra were measured on JEOL 400YH spectrometers. Chemical shifts for hydrogens are reported in parts per million (ppm, δ scale) downfield from tetramethylsilane ($\delta = 0$), multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet), and coupling constant (Hz). Detection and analysis of compounds by gas chromatography (Shimazu GC-2010 plus) and gas chromatography mass spectrometry were performed (Shimazu GC-2010 plus and Shimazu GCMS-TQ8040). HRMS spectra were determined on a Bruker Apex IV Fourier Transform Mass Spectrometer (EI) or Fourier Transform Ion Cyclotron Resonance Mass Spectrometer (ESI).

5. General procedure A for the preparation of starting materials


To a mixture of phenol **1** (1.0 equiv.) and K_2CO_3 or KOH (2.0 equiv.) was added DMF, and it was stirred at 60 °C for 1 h. Then 2-bromoacetaldehyde ethyl acetal (1.5 equiv.) was added. The mixture was stirred for about 6 h under reflux until the reaction was completed based on TLC analysis. It was cooled to room temperature and extracted with EtOAc (50 mL \times 3). The combined organic layers were subsequently washed with 5% NaOH aqueous solution and water, dried over $MgSO_4$ and concentrated under reduced pressure. The residual crude product was finally purified by flash silica gel column chromatography (eluting with petroleum ether/ethyl acetate) to afford the desired 2-aryloxyacetaldehyde diethyl acetals.

(2,2-Diethoxyethoxy)benzene (**1a**)¹




The general procedure A was followed with phenol (1.0 g, 10.6 mmol), KOH (1.19 g, 21.2 mmol) and 2-bromoacetaldehyde diethyl acetal (3.13 g, 15.9 mmol) in DMF (15 mL). **1a** was afforded as a colorless liquid (1.9 g, 9.05 mmol, 85%). ¹H NMR (400 MHz, $CDCl_3$) δ 7.30 – 7.23 (m, 2H), 6.97 – 6.89 (m, 3H), 4.84 (t, J = 5.2 Hz, 1H), 4.00 (d, J = 5.2 Hz, 2H), 3.80 – 3.72 (m, 2H), 3.67 – 3.59 (m, 2H), 1.24 (t, J = 7.1 Hz, 6H); ¹³C NMR (101 MHz, $CDCl_3$) δ 158.86, 129.51, 121.06, 114.73, 100.61, 68.54, 62.53, 15.43.

1-(2,2-Diethoxyethoxy)-2-fluorobenzene (**1b**)²




The general procedure A was followed with 2-fluorophenol (5.0 g, 44.6 mmol), K_2CO_3 (12.3 g, 89.2 mmol) and 2-bromoacetaldehyde diethyl acetal (13.18 g, 66.9 mmol) in DMF (35 mL). **1b** was afforded as a colorless liquid (7.98 g, 38 mmol, 85%). ¹H NMR (400 MHz, $CDCl_3$) δ 7.09 – 6.99 (m, 3H), 6.91 – 6.89 (m, 1H), 4.86 (t, J = 5.2 Hz, 1H), 4.07 (d, J = 5.2 Hz, 2H), 3.82 – 3.75 (m, 2H), 3.69 – 3.61 (m, 2H), 1.25 (t, J = 7.1 Hz, 6H); ¹³C NMR (101 MHz, $CDCl_3$) δ 152.76 (d, J = 246 Hz), 146.68 (d, J = 11.1 Hz), 124.16 (d, J = 3.0 Hz), 121.46 (d, J = 7.1 Hz), 116.15 (d, J = 18.2 Hz), 115.19, 100.61, 70.16, 62.93, 15.41.

1-Chloro-2-(2,2-diethoxyethoxy)benzene (**1c**)¹



The general procedure A was followed with 2-chlorophenol (5.0 g, 38.9 mmol), K_2CO_3 (10.74 g, 77.8 mmol) and 2-bromoacetaldehyde diethyl acetal (11.5 g, 58.4 mmol) in DMF (35 mL). **1c** was afforded as a colorless liquid (6.55 g, 26.7 mmol, 69%). ¹H NMR (400 MHz, $CDCl_3$) δ 7.38 (dd, J = 7.9, 1.6 Hz, 1H), 7.29 – 7.20 (m, 1H), 6.97 – 6.90 (m, 2H), 4.90 (t, J = 5.2 Hz, 1H), 4.08 (d, J = 5.3 Hz, 2H), 3.87 – 3.80 (m, 2H), 3.75 – 3.68 (m, 2H), 1.28 (t, J = 7.1 Hz, 6H); ¹³C NMR (101 MHz, $CDCl_3$) δ 154.15, 130.15, 127.71, 122.89, 121.65, 113.78, 100.53, 70.04, 63.22, 15.24.


1-Bromo-2-(2,2-diethoxyethoxy)benzene (**1d**)¹



The general procedure A was followed with 2-bromophenol (10.50 g, 60.7 mmol), K_2CO_3 (16.80 g, 121.4 mmol) and 2-bromoacetaldehyde diethyl acetal (17.95 g, 91.1 mmol) in DMF (35 mL). **1d** was afforded as a colorless liquid (14.05 g, 48.6 mmol, 80%). ¹H NMR (400 MHz, $CDCl_3$) δ 7.53 (dd, J = 7.8, 1.7 Hz, 1H), 7.24 – 7.23 (m, 1H), 6.91 – 6.89 (m, 1H), 6.86 – 6.81 (m, 1H), 4.88 (t, J = 5.2 Hz, 1H), 4.05 (d, J = 5.2 Hz, 2H), 3.85 – 3.77 (m,


2H), 3.74 – 3.67 (m, 2H), 1.26 (t, $J = 7.1$ Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 154.89, 113.20, 128.32, 122.02, 113.26, 112.05, 100.99, 69.96, 63.29, 15.25.

1-(2,2-Diethoxyethoxy)-2-iodobenzene (**1e**)³




The general procedure A was followed with 2-iodophenol (5 g, 22.7 mmol), K_2CO_3 (6.27 g, 45.4 mmol) and 2-bromoacetaldehyde diethyl acetal (6.7 g, 34 mmol) in DMF (35 mL). **1e** was afforded as a colorless liquid (4.74 g, 14.08 mmol, 62%). ^1H NMR (400 MHz, CDCl_3) δ 7.76 (dd, $J = 7.8, 1.7$ Hz, 1H), 7.28 – 7.25 (m, 1H), 6.81 (dd, $J = 8.2, 1.2$ Hz, 1H), 6.73 – 6.69 (m, 1H), 4.89 (t, $J = 5.2$ Hz, 1H), 4.03 (d, $J = 5.2$ Hz, 2H), 3.86 – 3.78 (m, 2H), 3.76 – 3.69 (m, 2H), 1.27 (t, $J = 7.1$ Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 157.06, 139.31, 129.32, 122.66, 112.14, 100.57, 86.32, 70.00, 63.31, 15.29.

1-(*Tert*-butyl)-2-(2,2-diethoxyethoxy) benzene (**1f**)




The general procedure A was followed with 2-*tert*-butylphenol (2.9 g, 19.3 mmol), K_2CO_3 (2.2 g, 38.9 mmol) and 2-bromoacetaldehyde diethyl acetal (5.7 g, 28.9 mmol) in DMF (35 mL). **1f** was afforded as a colorless liquid (2.33 g, 8.76 mmol, 45%). ^1H NMR (400 MHz, CDCl_3) δ 7.29 (dd, $J = 7.7, 1.6$ Hz, 1H), 7.18 – 7.14 (m, 1H), 6.92 – 6.88 (m, 1H), 6.84 (dd, $J = 8.2, 1.1$ Hz, 1H), 4.95 (t, $J = 5.4$ Hz, 1H), 4.02 (d, $J = 5.4$ Hz, 2H), 3.81 – 3.74 (m, 2H), 3.69 – 3.62 (m, 2H), 1.40 (s, 9H), 1.25 (t, $J = 7.0$ Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 157.33, 138.17, 127.17, 126.80, 120.67, 111.82, 100.63, 67.80, 62.28, 34.99, 29.86, 15.47. HRMS (EI) m/z calcd for $\text{C}_{16}\text{H}_{26}\text{O}_3$ [M]⁺ 266.1882, found 266.1876.

1-(2,2-Diethoxyethoxy)-2-methylbenzene (**1g**)⁴




The general procedure A was followed with *o*-cresol (5.0 g, 46.3 mmol), K_2CO_3 (12.8 g, 92.6 mmol) and 2-bromoacetaldehyde diethyl acetal (13.7 g, 69.5 mmol) in DMF (35 mL). **1g** was afforded as a colorless liquid (6.7 g, 29.9 mmol, 65%). ^1H NMR (400 MHz, CDCl_3) δ 7.15 (t, $J = 7.0$ Hz, 2H), 6.88 (td, $J = 7.4, 0.6$ Hz, 1H), 6.83 (d, $J = 8.4$ Hz, 1H), 4.88 (t, $J = 5.3$ Hz, 1H), 4.03 (d, $J = 5.3$ Hz, 2H), 3.86 – 3.74 (m, 2H), 3.73 – 3.62 (m, 2H), 2.26 (s, 3H), 1.28 (t, $J = 7.1$ Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 156.61, 130.55, 126.74, 126.66, 120.54, 111.01, 100.68, 68.72, 62.62, 16.11, 15.25.

2-(2,2-Diethoxyethoxy)-1,1'-biphenyl (**1h**)




The general procedure A was followed with 2-phenylphenol (4.0 g, 23.5 mmol), K_2CO_3 (6.5 g, 47 mmol) and 2-bromoacetaldehyde diethyl acetal (6.95 g, 35.3 mmol) in DMF (35 mL). **1h** was afforded as a colorless liquid (5.5 g, 19.2 mmol, 82%). ^1H NMR (400 MHz, CDCl_3) δ 7.57 (dd, $J = 5.2, 3.3$ Hz, 2H), 7.39 – 7.26 (m, 5H), 7.05 – 7.01 (m, 1H), 6.96 (dd, $J = 8.2, 0.7$ Hz, 1H), 4.71 (t, $J = 5.3$ Hz, 1H), 3.98 (d, $J = 5.2$ Hz, 2H), 3.71 – 3.64 (m, 2H), 3.55 – 3.47 (m, 2H), 1.17 (t, $J = 7.0$ Hz, 6H); ^{13}C NMR (101 MHz, CDCl_3) δ 155.57, 138.51, 131.04, 130.99, 129.77, 128.72, 127.90, 126.93, 121.38, 112.65, 100.87, 69.43, 63.17, 15.42. HRMS (EI) m/z calcd for $\text{C}_{18}\text{H}_{22}\text{O}_3$ [M]⁺ 286.1569, found 286.1633.

1-(2,2-Diethoxyethoxy)-4-nitrobenzene (**1i**)⁵




The general procedure A was followed with 4-nitrophenol (5.0 g, 36 mmol), K₂CO₃ (10 g, 72 mmol) and 2-bromoacetaldehyde diethyl acetal (10.64 g, 54 mmol) in DMF (70 mL). **1i** was afforded as a pale-yellow liquid (3.7 g, 14.5 mmol, 40%). ¹H NMR (400 MHz, CDCl₃) δ 8.22 – 8.15 (m, 2H), 7.02 – 6.97 (m, 2H), 4.86 (t, *J* = 5.1 Hz, 1H), 4.10 (d, *J* = 5.2 Hz, 2H), 3.85 – 3.74 (m, 2H), 3.70 – 3.60 (m, 2H), 1.25 (q, *J* = 7.0 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 163.60, 141.63, 125.81, 114.64, 100.20, 69.08, 63.02, 15.30.

Isopropyl 4-(2,2-diethoxyethoxy) benzoate (**1j**)




The general procedure A was followed with isopropyl 4-hydroxybenzoate (5.0 g, 27.8 mmol), K₂CO₃ (7.67 g, 55.6 mmol) and 2-bromoacetaldehyde diethyl acetal (8.2 g, 41.7 mmol) in DMF (35 mL). **1j** was afforded as a colorless liquid (6.5 g, 21.9 mmol, 79%). ¹H NMR (400 MHz, CDCl₃) δ 8.00 – 7.96 (m, 2H), 6.94 – 6.92 (m, 2H), 5.25 – 5.19 (m, 1H), 4.85 (t, *J* = 5.2 Hz, 1H), 4.05 (d, *J* = 5.1 Hz, 2H), 3.81 – 3.74 (m, 2H), 3.68 – 3.60 (m, 2H), 1.35 (d, *J* = 8Hz, 6H), 1.25 (t, *J* = 7.1 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 165.89, 162.21, 131.54, 123.69, 114.18, 100.42, 68.60, 68.04, 62.87, 22.09, 15.42. HRMS (ESI) *m/z* calcd for C₁₆H₂₄O₅ [M + H]⁺ 297.1702, found 297.1694.

1-Bromo-4-(2,2-diethoxyethoxy)benzene (**1k**)¹




The general procedure A was followed with 4-bromophenol (3.0 g, 17.3 mmol), KOH (1.94 g, 34.6 mmol) and 2-bromoacetaldehyde diethyl acetal (5.1 g, 25.9 mmol) in DMF (30 mL). **1k** was afforded as a colorless liquid (3.3 g, 11.4 mmol, 66%). ¹H NMR (400 MHz, CDCl₃) δ 7.38 – 7.35 (m, 2H), 6.82 – 6.80 (m, 2H), 4.82 (t, *J* = 5.2 Hz, 1H), 3.97 (d, *J* = 5.2 Hz, 2H), 3.80 – 3.72 (m, 2H), 3.67 – 3.59 (m, 2H), 1.25 (t, *J* = 7.1 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 157.64, 132.15, 116.38, 113.09, 100.29, 68.63, 62.62, 15.28.

1-(2,2-Diethoxyethoxy)-4-methoxybenzene (**1l**)¹




The general procedure A was followed with 4-methoxyphenol (3.0 g, 24.2 mmol), KOH (2.7 g, 48.4 mmol) and 2-bromoacetaldehyde diethyl acetal (7.15 g, 36.3 mmol) in DMF (30 mL). **1l** was afforded as a colorless liquid (5.1 g, 21.3 mmol, 88%). ¹H NMR (400 MHz, CDCl₃) δ 6.88 – 6.80 (m, 4H), 4.82 (t, *J* = 5.2 Hz, 1H), 3.97 (d, *J* = 5.2 Hz, 2H), 3.81 – 3.72 (m, 5H), 3.67 – 3.59 (m, 2H), 1.25 (t, *J* = 7.1 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 153.87, 152.65, 115.49, 114.41, 100.41, 69.10, 62.32, 55.48, 15.19.

1-(2,2-Diethoxyethoxy)naphthalene (**1m**)¹




The general procedure A was followed with 1-naphthol (5.0 g, 34.7 mmol), K_2CO_3 (9.6 g, 69.4 mmol) and 2-bromoacetaldehyde diethyl acetal (10.26 g, 52.1 mmol) in DMF (35 mL). **1m** was afforded as a colorless liquid (6.25 g, 24 mmol, 69%). 1H NMR (400 MHz, $CDCl_3$) δ 8.31 – 8.29 (m, 1H), 7.82 – 7.79 (m, 1H), 7.52 – 7.44 (m, 3H), 7.37 (t, $J = 8.0$ Hz, 1H), 6.83 (d, $J = 7.2$ Hz, 1H), 5.02 (t, $J = 5.3$ Hz, 1H), 4.20 (d, $J = 5.2$ Hz, 2H), 3.88 – 3.81 (m, 2H), 3.76 – 3.68 (m, 2H), 1.30 (t, $J = 8.0$ Hz, 6H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 154.21, 134.40, 127.32, 126.28, 125.70, 125.55, 125.07, 121.92, 120.46, 104.80, 100.56, 68.77, 62.60, 15.30.

2-(2,2-Diethoxyethoxy)-1,4-dichlorobenzene (**1n**)




The general procedure A was followed with 2, 5-dichlorophenol (5.0 g, 30.67 mmol), K_2CO_3 (8.46 g, 61.34 mmol) and 2-bromoacetaldehyde diethyl acetal (9.06 g, 46 mmol) in DMF (35 mL). **1n** was afforded as a colorless liquid (6.2 g, 22.2 mmol, 72%). 1H NMR (400 MHz, $CDCl_3$) δ 7.26 (d, $J = 8.4$ Hz, 1H), 6.94 (d, $J = 2.3$ Hz, 1H), 6.88 (dd, $J = 8.3, 2.3$ Hz, 1H), 4.86 (t, $J = 5.2$ Hz, 1H), 4.03 (d, $J = 5.2$ Hz, 2H), 3.84 – 3.76 (m, 2H), 3.71 – 3.64 (m, 2H), 1.25 (t, $J = 8.0$ Hz, 6H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 154.70, 133.06, 130.78, 121.69, 121.50, 114.23, 100.60, 70.27, 63.53, 15.43. HRMS (ESI) m/z calcd for $C_{12}H_{16}Cl_2O_3$ [$M + Na$] $^+$ 301.0374, found 301.0374.

2-(2,2-Diethoxyethoxy)-1,4-dimethylbenzene (**1o**)⁶




The general procedure A was followed with 2, 5-dimethylphenol (5.0 g, 40.98 mmol), K_2CO_3 (11.3 g, 81.96 mmol) and 2-bromoacetaldehyde diethyl acetal (9.06 g, 46 mmol) in DMF (35 mL). **1o** was afforded as a colorless liquid (12.1 g, 61.5 mmol, 43%). 1H NMR (400 MHz, $CDCl_3$) δ 7.00 (d, $J = 7.5$ Hz, 1H), 6.67 (d, $J = 7.5$ Hz, 1H), 6.64 (s, 1H), 4.85 (t, $J = 5.3$ Hz, 1H), 3.99 (d, $J = 5.3$ Hz, 2H), 3.82 – 3.74 (m, 2H), 3.69 – 3.61 (m, 2H), 2.30 (s, 3H), 2.19 (s, 3H), 1.25 (t, $J = 6$ Hz, 6H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 156.49, 136.48, 130.30, 123.58, 121.07, 112.08, 100.74, 68.72, 62.67, 21.32, 15.77, 15.32.

1,2-Dichloro-3-(2,2-diethoxyethoxy) benzene (**1p**)




The general procedure A was followed with 2,3-dichlorophenol (3.0 g, 18.4 mmol), Cs_2CO_3 (9.0 g, 27.6 mmol) and 2-bromoacetaldehyde diethyl acetal (5.4 g, 27.6 mmol) in DMF (35 mL). **1p** was afforded as a colorless liquid (3.78 g, 13.55 mmol, 74%). 1H NMR (400 MHz, $CDCl_3$) δ 7.10 (t, $J = 8.1$ Hz, 1H), 7.05 (dd, $J = 8.2, 1.5$ Hz, 1H), 6.82 (dd, $J = 8.1, 1.5$ Hz, 1H), 4.85 (t, $J = 5.2$ Hz, 1H), 4.03 (d, $J = 5.2$ Hz, 2H), 3.82 – 3.75 (m, 2H), 3.70 – 3.63 (m, 2H), 1.23 (t, $J = 7.1$ Hz, 6H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 154.70, 133.06, 130.78, 121.69, 121.50, 114.23, 100.60, 70.27, 63.53, 15.43. HRMS (EI) m/z calcd for $C_{12}H_{16}Cl_2O_3$ [M] $^+$ 278.0476, found 278.0472.

1-(2,2-Diethoxyethoxy)-2,4-dimethylbenzene (**1q**)




The general procedure A was followed with 2,5-dimethylphenol (5.0 g, 40.98 mmol), K_2CO_3 (11.3 g, 81.96 mmol) and 2-bromoacetaldehyde diethyl acetal (12.1 g, 61.5 mmol) in DMF (55 mL). **1q** was afforded as a colorless liquid (4.65 g, 19.54 mmol, 48%). 1H NMR (400 MHz, $CDCl_3$) δ 6.94 – 6.92 (m, 2H), 6.70 (d, $J = 8.1$ Hz, 1H), 4.84 (t, $J = 5.3$ Hz, 1H), 3.88 (d, $J = 5.3$ Hz, 2H), 3.81 – 3.74 (m, 2H), 3.69 – 3.61 (m, 2H), 2.25 (s, 3H), 2.20 (s, 3H), 1.25 (t, $J = 8$ Hz, 6H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 154.72, 131.60, 129.94, 127.03, 126.75, 111.29, 100.87, 69.10, 62.81, 20.56, 16.28, 15.48. HRMS (EI) m/z calcd for $C_{14}H_{22}O_3$ [M] $^+$ 238.1569, found 238.1563.

2,4-Dibromo-1-(2,2-diethoxyethoxy) benzene (**1r**)




The general procedure A was followed with 2, 4-dibromophenol (3.0 g, 11.9 mmol), K_2CO_3 (3.28 g, 23.8 mmol) and 2-bromoacetaldehyde diethyl acetal (3.53 g, 17.9 mmol) in DMF (55 mL). **1r** was afforded as a colorless liquid (2.7 g, 7.34 mmol, 62%). 1H NMR (400 MHz, $CDCl_3$) δ 7.66 (d, $J = 2.4$ Hz, 1H), 7.35 (dd, $J = 8.7, 2.3$ Hz, 1H), 6.79 (d, $J = 8.8$ Hz, 1H), 4.86 (t, $J = 5.2$ Hz, 1H), 4.02 (d, $J = 5.2$ Hz, 2H), 3.84 – 3.77 (m, 2H), 3.72 – 3.65 (m, 2H), 1.25 (t, $J = 6$ Hz, 6H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 154.51, 135.57, 131.29, 114.67, 113.37, 113.17, 100.68, 70.41, 63.63, 15.46. HRMS (EI) m/z calcd for $C_{12}H_{16}Br_2O_3$ $[M+2]^+$ 367.9466, found 367.9435.

1,4-Dibromo-2,5-bis(2,2-diethoxyethoxy)benzene (**1s**)⁷




The general procedure A was followed with hydroquinone (10 g, 37.3 mmol), KOH (8.36 g, 149.2 mmol) and 2-bromoacetaldehyde diethyl acetal (3.53 g, 17.9 mmol) in DMSO (125 mL). **1s** was afforded as a white solid (13.1 g, 26.2 mmol, 70%), Mp 61.5-62.1 °C. 1H NMR (400 MHz, $CDCl_3$) δ 7.14 (s, 2H), 4.84 (t, $J = 5.2$ Hz, 2H), 3.99 (d, $J = 5.2$ Hz, 4H), 3.83 – 3.75 (m, 4H), 3.71–3.65 (m, 4H), 1.25 (t, $J = 7.1$ Hz, 12H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 150.04, 118.85, 111.10, 100.48, 71.00, 63.17, 15.27.

1,5-Bis(2,2-diethoxyethoxy)naphthalene (**1t**)⁸




The general procedure A was followed with 1,5-dihydroxynaphthalene (5.0 g, 31.25 mmol), KOH (7 g, 125 mmol) and 2-bromoacetaldehyde diethyl acetal (9.24 g, 46.9 mmol) in DMF (125 mL). **1t** was afforded as a pale-yellow solid (2.04 g, 5.19 mmol, 17%), Mp 140.6 - 141.8 °C. 1H NMR (400 MHz,) δ 7.87 (d, $J = 8.4$ Hz, 2H), 7.36 (t, $J = 8.0$ Hz, 2H), 6.85 (d, $J = 7.6$ Hz, 2H), 5.01 (t, $J = 5.2$ Hz, 2H), 4.18 (d, $J = 5.2$ Hz, 4H), 3.89 - 3.79 (m, 4H), 3.79 – 3.66 (m, 4H), 1.29 (t, $J = 7.0$ Hz, 12H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 154.08, 126.82, 125.08, 114.63, 105.67, 100.65, 68.94, 62.72, 15.36.

1-(2,2-Diethoxyethoxy)-3-fluorobenzene (**1u**)




The general procedure A was followed with 3-fluorophenol (3.6 g, 32.1 mmol), K_2CO_3 (6.8 g, 49 mmol) and 2-bromoacetaldehyde diethyl acetal (5.5 g, 24.1 mmol) in DMF (15 mL). **1u** was afforded as a colorless liquid (5.5 g, 24.1 mmol, 75%). 1H NMR (400 MHz, $CDCl_3$) δ 7.24 – 7.18 (m, 1H), 6.72 – 6.62 (m, 3H), 4.83 (t, $J = 5.2$ Hz, 1H), 3.99 (d, $J = 5.2$ Hz, 2H), 3.81 – 3.73 (m, 2H), 3.67 – 3.60 (m, 2H), 1.25 (t, $J = 7.1$ Hz, 6H); ^{13}C NMR (101 MHz, $CDCl_3$) δ 163.62 (d, $J = 246$ Hz), 160.00 (d, $J = 10.8$ Hz), 130.26 (d, $J = 10.1$ Hz), 110.38 (d, $J = 2.5$ Hz), 107.86 (d, $J = 21.3$ Hz), 102.52 (d, $J = 25.0$ Hz), 100.40, 68.77, 62.75, 15.39. HRMS (EI) m/z calcd for $C_{12}H_{17}FO_3$ $[M]^+$ 228.1162, found 228.1164.

1-Chloro-3-(2,2-diethoxyethoxy)benzene (**1v**)¹




The general procedure A was followed with 3-chlorophenol (5.0 g, 38.8 mmol), KOH (4.37 g, 78 mmol) and 2-bromoacetaldehyde diethyl acetal (11.5 g, 58.4 mmol) in *N,N*-dimethylacetamide (DMAC) (50 mL). **1v** was afforded as a colorless liquid (5.2 g, 21.2 mmol, 55%). ¹H NMR (400 MHz, CDCl₃) δ 7.21-7.16 (m, 1H), 6.96 – 6.91 (m, 2H), 6.83 – 6.78 (m, 1H), 4.82 (t, *J* = 5.2 Hz, 1H), 3.99 (d, *J* = 5.2 Hz, 2H), 3.81 – 3.70 (m, 2H), 3.69 – 3.58 (m, 2H), 1.25 (dd, *J* = 8.8, 5.3 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 159.25, 134.72, 130.10, 121.08, 115.10, 112.97, 100.27, 68.64, 62.60, 15.24.

1-Bromo-3-(2,2-diethoxyethoxy)benzene (**1w**)¹




The general procedure A was followed with 3-bromophenol (3.26 g, 18.8 mmol), KOH (2.11 g, 37.6 mmol) and 2-bromoacetaldehyde diethyl acetal (5.6 g, 28.2 mmol) in DMAC (35 mL). **1w** was afforded as a colorless liquid (3.8 g, 13.1 mmol, 70%). ¹H NMR (400 MHz, CDCl₃) δ 7.16 – 7.07 (m, 3H), 6.87 – 6.84 (m, 1H), 4.82 (t, *J* = 5.2 Hz, 1H), 3.98 (d, *J* = 5.2 Hz, 2H), 3.80 – 3.73 (m, 2H), 3.67 – 3.59 (m, 2H), 1.25 (t, *J* = 7.1 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 159.16, 130.35, 123.88, 122.54, 117.84, 113.34, 100.14, 68.48, 62.48, 15.18.

1-(*Tert*-butyl)-3-(2,2-diethoxyethoxy)benzene (**1x**)




The general procedure A was followed with 3-*tert*-butylphenol (2.9 g, 19.3 mmol), KOH (2.16 g, 38.6 mmol) and 2-bromoacetaldehyde diethyl acetal (5.7 g, 28.95 mmol) in DMF (35 mL). **1x** was afforded as a colorless liquid (1.81 g, 6.80 mmol, 35%). ¹H NMR (400 MHz, CDCl₃) δ 7.22 – 7.18 (m, 1H), 6.99 – 6.97 (m, 2H), 6.73 – 6.70 (m, 1H), 4.84 (t, *J* = 5.2 Hz, 1H), 4.00 (d, *J* = 5.2 Hz, 2H), 3.80 – 3.72 (m, 2H), 3.67 – 3.60 (m, 2H), 1.29 (s, 9H), 1.25 (t, *J* = 7.1 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 158.53, 153.02, 129.03, 118.23, 112.74, 110.90, 100.63, 68.41, 62.52, 34.86, 31.43, 15.47. HRMS (EI) *m/z* calcd for C₁₆H₂₆O₃ [M]⁺ 266.1882, found 266.1885.

1-(2,2-Diethoxyethoxy)-3-methylbenzene (**1y**)¹




The general procedure A was followed with 3-methylphenol (5 g, 46.3 mmol), KOH (5.2 g, 92.6 mmol) and 2-bromoacetaldehyde diethyl acetal (5.7 g, 28.95 mmol) in DMF (50 mL). **1y** was afforded as a colorless liquid (7.8 g, 35 mmol, 76%). ¹H NMR (400 MHz, CDCl₃) δ 7.13-7.16 (m, 1H), 6.70 – 6.76 (m, 3H), 4.82 (t, *J* = 5.2 Hz, 1H), 3.98 (d, *J* = 5.3 Hz, 2H), 3.80 – 3.68 (m, 2H), 3.68 – 3.56 (m, 2H), 2.30 (s, 3H), 1.27 – 1.20 (m, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 158.50, 139.40, 129.13, 121.61, 115.58, 111.53, 100.43, 68.51, 62.48, 21.36, 15.32.

(2,2-Diethoxyethyl)(*p*-tolyl)sulfane (**3a**)⁴




The general procedure A was followed with 4-methylbenzenethiol (2.48 g, 20 mmol), K₂CO₃ (3.3 g, 24 mmol) and 2-bromoacetaldehyde diethyl acetal (4.7 g, 24 mmol) in DMF (50 mL). **3a** was afforded as a colorless liquid (4.08 g, 17 mmol, 85%). ¹H NMR (400 MHz, CDCl₃) δ 7.29 (d, *J* = 8.2 Hz, 2H), 7.09 (d, *J* = 8.2 Hz, 2H), 4.62 (t, *J* = 5.6 Hz, 1H), 3.70 – 3.62 (m, 2H), 3.57 – 3.50 (m, 2H), 3.09 (d, *J* = 5.5 Hz, 2H), 2.31 (s, 3H), 1.19 (t, *J* = 6.0 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 136.38, 132.70, 130.24, 129.78, 101.86, 62.17, 38.17, 21.13, 15.37.

(4-Chlorophenyl) (2,2-diethoxyethyl) sulfide (**3b**)⁹




The general procedure A was followed with 4-chlorothiophenol (4.3 g, 30 mmol), K₂CO₃ (8.3 g, 45 mmol) and 2-bromoacetaldehyde diethyl acetal (8.9 g, 45 mmol) in DMF (50 mL). **3b** was afforded as a colorless liquid (7.05 g, 27 mmol, 90%). ¹H NMR (400 MHz, CDCl₃) δ 7.34 – 7.29 (m, 2H), 7.26 – 7.21 (m, 2H), 4.63 (t, *J* = 5.6 Hz, 1H), 3.72 – 3.62 (m, 2H), 3.59 – 3.48 (m, 2H), 3.10 (d, *J* = 5.5 Hz, 2H), 1.19 (t, *J* = 7.1 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 135.09, 132.11, 130.71, 129.02, 101.80, 62.51, 37.83, 15.31.

(2,2-Diethoxyethyl) (*o*-tolyl)sulfane (**3c**)¹⁰




The general procedure A was followed with *o*-toluenethiol (2.48 g, 20 mmol), K₂CO₃ (3.3 g, 24 mmol) and 2-bromoacetaldehyde diethyl acetal (4.7 g, 24 mmol) in DMF (50 mL). **3c** was afforded as a colorless liquid (3.84 g, 16 mmol, 80%). ¹H NMR (400 MHz, CDCl₃) δ 7.33 (d, *J* = 7.9 Hz, 1H), 7.18 – 7.06 (m, 3H), 4.66 (t, *J* = 5.6 Hz, 1H), 3.71 – 3.64 (m, 2H), 3.59 – 3.51 (m, 2H), 3.11 (d, *J* = 5.6 Hz, 2H), 2.39 (s, 3H), 1.21 (t, *J* = 7.0 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 137.86, 135.71, 130.22, 128.52, 126.53, 125.99, 101.66, 62.11, 36.79, 20.57, 15.38.

(2-Chlorophenyl) (2,2-diethoxyethyl) sulfane (**3d**)⁹



The general procedure A was followed with 2-chlorothiophenol (4.30 g, 30 mmol), K₂CO₃ (8.30 g, 60 mmol) and 2-bromoacetaldehyde diethyl acetal (8.9 g, 45 mmol) in DMF (50 mL). **3d** was afforded as a colorless liquid (7.52 g, 28.8 mmol, 96%). ¹H NMR (400 MHz, CDCl₃) δ 7.40 – 7.35 (m, 2H), 7.20 (td, *J* = 7.6, 1.4 Hz, 1H), 7.14 – 7.09 (m, 1H), 4.69 (t, *J* = 5.5 Hz, 1H), 3.73 – 3.65 (m, 2H), 3.60 – 3.52 (m, 2H), 3.15 (d, *J* = 5.5 Hz, 2H), 1.20 (t, *J* = 7.1 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 135.77, 133.89, 129.79, 129.28, 127.16, 126.86, 101.74, 62.38, 36.45, 15.35.

(2-Bromophenyl)(2,2-diethoxyethyl)sulfane (**3e**)¹¹




The general procedure A was followed with 2-bromothiophenol (5.67 g, 30 mmol), K₂CO₃ (8.28 g, 60 mmol) and 2-bromoacetaldehyde diethyl acetal (8.9 g, 45 mmol) in DMF (50 mL). **3e** was afforded as a colorless liquid (8.7 g, 28.5 mmol, 95%). ¹H NMR (400 MHz, CDCl₃) δ 7.53 (dd, *J* = 8.0, 1.3 Hz, 1H), 7.36 (dd, *J* = 7.9, 1.5 Hz, 1H), 7.29 – 7.22 (m, 1H), 7.06 – 6.99 (m, 1H), 4.70 (t, *J* = 5.6 Hz, 1H), 3.73 – 3.66 (m, 2H), 3.60 – 3.54 (m, 2H), 3.15 (d, *J* = 5.5 Hz, 2H), 1.20 (t, *J* = 7.1 Hz, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 137.81, 133.05, 128.88, 127.77, 126.89, 123.90, 101.65, 62.39, 36.86, 15.34.

6. General procedure B for the preparation of benzofurans and benzothiophenes


To a 25 mL Schlenk tube was added compound **1** or **3** (1 mmol), phosphoric acid (300 μ L, 4.8 equiv) and chlorobenzene (3 mL). The mixture was stirred at 130 $^{\circ}$ C for 12 h. Then the mixture was cooled to room temperature, the organic layer was separated and concentrated under reduced pressure. The residual was finally purified by flash silica gel column chromatography (eluting with petroleum ether/ethyl acetate) to afford the desired products.

Benzofuran (**2a**)¹²




2a was afforded as a colorless liquid (104 mg, 0.88 mmol, 88%). ¹H NMR (400 MHz, CDCl₃) δ 7.64 – 7.58 (m, 2H), 7.54 – 7.49 (m, 1H), 7.34 – 7.28 (m, 1H), 7.23 (dd, J = 7.3, 1.0 Hz, 1H), 6.78 (dd, J = 2.2, 0.8 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 155.04, 144.99, 127.50, 124.32, 122.82, 121.28, 111.51, 106.65.

7-Fluorobenzofuran (**2b**)¹³




2b was afforded as a colorless liquid (67 mg, 0.49 mmol, 49%). Due to the relatively low boiling point of the compound, some products evaporated away with the chlorobenzene solvent, resulting in low yield. ¹H NMR (400 MHz, CDCl₃) δ 7.66 (d, J = 2.1 Hz, 1H), 7.37 (dd, J = 7.8, 0.8 Hz, 1H), 7.19 – 7.14 (m, 1H), 7.06 – 7.01 (m, 1H), 6.83 – 6.81 (m, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 148.42 (d, J = 124 Hz), 145.86, 141.92, 130.96, 123.42, 116.88, 110.67, 107.12.

7-Chlorobenzofuran (**2c**)¹




2c was afforded as a colorless liquid (108 mg, 0.71 mmol, 71%). ¹H NMR (400 MHz, CDCl₃) δ 7.69 (d, J = 2.2 Hz, 1H), 7.50 (dd, J = 7.8, 0.9 Hz, 1H), 7.30 (dd, J = 7.8, 0.9 Hz, 1H), 7.17 (t, J = 7.8 Hz, 1H), 6.82 (d, J = 2.1 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 150.70, 145.64, 129.02, 124.42, 123.66, 119.74, 116.90, 107.11.

7-Bromobenzofuran (**2d**)¹⁴




2d was afforded as a colorless liquid (173 mg, 0.88 mmol, 88%). ¹H NMR (400 MHz, CDCl₃) δ 7.70 (d, J = 2.2 Hz, 1H), 7.56 – 7.46 (m, 2H), 7.13 (t, J = 7.8 Hz, 1H), 6.85 (d, J = 2.2 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 152.05, 145.82, 128.71, 127.60, 124.18, 120.52, 107.42, 104.59.

7-Iodobenzofuran (**2e**)³




2e was afforded as a pale-yellow liquid (137 mg, 0.56 mmol, 56%). ¹H NMR (400 MHz, CDCl₃) δ 7.69 (d, J = 2.2 Hz, 1H), 7.66 (dd, J = 7.7, 0.9 Hz, 1H), 7.55 (dd, J = 7.7, 1.0 Hz, 1H), 7.00 (t, J = 7.6 Hz, 1H), 6.88 (d, J = 2.3 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 155.30, 145.34, 133.39, 127.54, 124.66, 121.45, 107.79, 75.19.

7-(*Tert*-butyl)benzofuran (**2f**)




2f was afforded as a colorless liquid (148 mg, 0.85 mmol, 85%). ¹H NMR (400 MHz, CDCl₃) δ 7.64 (d, *J* = 2.2 Hz, 1H), 7.46 (dd, *J* = 7.0, 2.0 Hz, 1H), 7.20 – 7.15 (m, 2H), 6.75 (d, *J* = 2.1 Hz, 1H), 1.50 (s, 9H); ¹³C NMR (101 MHz, CDCl₃) δ 153.36, 144.06, 135.09, 127.99, 122.77, 120.90, 119.28, 106.49, 34.45, 29.95. HRMS (EI) *m/z* calcd for C₁₂H₁₄O [M]⁺ 174.1045, found 174.1037.

7-Methylbenzofuran (**2g**)¹⁵




2g was afforded as a colorless liquid (96 mg, 0.73 mmol, 73%). ¹H NMR (400 MHz, CDCl₃) δ 7.62 (d, *J* = 2.2 Hz, 1H), 7.45 – 7.40 (m, 1H), 7.16 – 7.05 (m, 2H), 6.75 (d, *J* = 2.2 Hz, 1H), 2.53 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 154.11, 144.67, 126.94, 125.14, 122.85, 121.73, 118.70, 106.86, 15.08.

7-Phenylbenzofuran (**2h**)³




2h was afforded as a colorless liquid (121 mg, 0.62 mmol, 62%). ¹H NMR (400 MHz, CDCl₃) δ 7.89 – 7.85 (m, 2H), 7.68 (d, *J* = 2.2 Hz, 1H), 7.58 (dd, *J* = 7.7, 1.2 Hz, 1H), 7.52 – 7.48 (m, 2H), 7.46 (dd, *J* = 7.5, 1.1 Hz, 1H), 7.41 – 7.37 (m, 1H), 7.34 – 7.30 (m, 1H), 6.83 (d, *J* = 2.1 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 152.35, 145.14, 136.67, 128.78, 128.75, 128.33, 127.82, 125.76, 123.98, 123.46, 120.56, 106.93.

7-Nitrobenzofuran (**2i**)⁵




2i was afforded as a pale-yellow liquid (64 mg, 0.39 mmol, 39%). ¹H NMR (400 MHz, CDCl₃) δ 8.55 (d, *J* = 2.0 Hz, 1H), 8.25 (dd, *J* = 9.2, 2.4 Hz, 1H), 7.79 (d, *J* = 2.4 Hz, 1H), 7.60 (d, *J* = 9.2 Hz, 1H), 6.94 (dd, *J* = 2.4, 1.2 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 157.69, 147.98, 144.20, 127.80, 120.22, 117.86, 111.78, 107.59.

Isopropyl benzofuran-5-carboxylate (**2j**)




2j was afforded as a white solid (91 mg, 0.44 mmol, 44%). ¹H NMR (400 MHz, CDCl₃) δ 8.35 (d, *J* = 1.6 Hz, 1H), 8.03 (dd, *J* = 8.7, 1.8 Hz, 1H), 7.69 (d, *J* = 2.2 Hz, 1H), 7.53 (d, *J* = 8.7 Hz, 1H), 6.85 (dd, *J* = 2.2, 0.7 Hz, 1H), 5.31 – 5.25 (m, 1H), 1.40 (d, *J* = 4 Hz, 6H); ¹³C NMR (101 MHz, CDCl₃) δ 166.42, 157.50, 146.29, 127.47, 126.13, 126.02, 123.75, 111.28, 107.26, 68.44, 22.17. HRMS (ESI) *m/z* calcd for C₁₂H₁₂O₃ [M + H]⁺ 205.0865, found 205.0864.

5-Bromobenzofuran (**2k**)¹




2k was afforded as a colorless liquid (185 mg, 0.94 mmol, 94%). ¹H NMR (400 MHz,) δ 7.72 (d, *J* = 1.2 Hz, 1H), 7.61 (d, *J* = 2.2 Hz, 1H), 7.38 (d, *J* = 1.5 Hz, 2H), 6.71 (d, *J* = 2.2 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 153.66, 146.12, 129.39, 127.14, 123.81, 115.77, 112.82, 106.11.

5-Methoxybenzofuran (**2l**)¹




2l was afforded as a colorless liquid (70 mg, 0.47 mmol, 47%). ¹H NMR (400 MHz, CDCl₃) δ 7.60 (d, *J* = 2.2 Hz, 1H), 7.39 (d, *J* = 9.0 Hz, 1H), 7.06 (d, *J* = 2.5 Hz, 1H), 6.90 (dd, *J* = 9.0, 2.6 Hz, 1H), 6.71 (dd, *J* = 2.2, 0.7 Hz, 1H), 3.85 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 155.99, 149.99, 145.80, 127.86, 113.14, 111.88, 106.77, 103.57, 29.79.

Naphtho[1,2-*b*]furan (**2m**)¹




2m was afforded as a colorless liquid (138 mg, 0.82 mmol, 82%). ¹H NMR (400 MHz, CDCl₃) δ 8.31 (d, *J* = 8.2 Hz, 1H), 7.93 (d, *J* = 8.2 Hz, 1H), 7.76 (d, *J* = 2.1 Hz, 1H), 7.66 (s, 2H), 7.61 – 7.57 (m, 1H), 7.51 – 7.46 (m, 1H), 6.90 (d, *J* = 2.0 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 150.71, 144.23, 131.56, 128.45, 126.45, 125.22, 123.55, 123.08, 121.64, 120.14, 119.87, 107.73.

4,7-Dichlorobenzofuran (**2n**)¹




2n was afforded as a white solid (129 mg, 0.69 mmol, 69%), Mp 56.5-57.0 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.72 (d, *J* = 2.2 Hz, 1H), 7.25 (d, *J* = 8.4 Hz, 1H), 7.19 (d, *J* = 8.3 Hz, 1H), 6.92 (d, *J* = 2.2 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 150.77, 146.21, 128.19, 124.92, 124.82, 123.53, 115.66, 106.19.

4,7-Dimethylbenzofuran (**2o**)⁶




2o was afforded as a colorless liquid (108 mg, 0.74 mmol, 74%). ¹H NMR (400 MHz, CDCl₃) δ 7.62 (d, *J* = 2.2 Hz, 1H), 7.00 (d, *J* = 7.4 Hz, 1H), 6.94 (d, *J* = 7.4 Hz, 1H), 6.78 (d, *J* = 2.1 Hz, 1H), 2.50 (s, 3H), 2.49 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 153.69, 144.09, 128.31, 126.60, 124.88, 122.89, 118.78, 105.39, 18.34, 14.82.

6,7-Dichlorobenzofuran (**2p**)¹⁶




2p was afforded as a white solid (119 mg, 0.64 mmol, 64%), Mp 40.3-41.2 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.69 (d, *J* = 2.2 Hz, 1H), 7.43 (d, *J* = 8.3 Hz, 1H), 7.34 (d, *J* = 8.4 Hz, 1H), 6.81 (d, *J* = 2.2 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 151.67, 146.49, 128.74, 127.40, 125.02, 119.69, 116.26, 107.48. HRMS (EI) *m/z* calcd for C₈H₄Cl₂O [M]⁺ 185.9639, found 185.9633.

5,7-Dimethylbenzofuran (**2q**)¹⁷




2q was afforded as a colorless liquid (124 mg, 0.85 mmol, 85%). ¹H NMR (400 MHz, CDCl₃) δ 7.57 (d, *J* = 2.1 Hz, 1H), 7.20 (s, 1H), 6.91 (s, 1H), 6.67 (d, *J* = 2.2 Hz, 1H), 2.48 (s, 3H), 2.40 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 152.44, 144.67, 132.13, 126.94, 126.45, 120.98, 118.31, 106.32, 21.22, 15.00.

5,7-Dibromobenzofuran (**2r**)




2r was afforded as a white solid (153 mg, 0.56 mmol, 56%), ¹H NMR (400 MHz, CDCl₃) δ 7.70 (d, *J* = 2.2 Hz, 1H), 7.68 (d, *J* = 1.8 Hz, 1H), 7.60 (d, *J* = 1.8 Hz, 1H), 6.80 (d, *J* = 2.1 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 151.29, 146.88, 130.11, 129.73, 123.23, 116.06, 107.13, 105.06. HRMS (EI) *m/z* calcd for C₈H₄Br₂O [M]⁺ 273.8629, found 273.8622.

4,8-Dibromobenzo[1,2-*b*:4,5-*b'*]difuran (**2s**)⁷




2s was afforded as a yellow solid (177 mg, 0.56 mmol, 56%), Mp 209.9–212.6 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.76 (d, *J* = 2.2 Hz, 2H), 6.98 (d, *J* = 2.2 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 148.94, 146.60, 127.19, 107.53, 93.94.

Naphtho[1,2-*b*:5,6-*b'*]difuran (**2t**)¹⁸




2t was afforded as a white solid (93 mg, 0.45 mmol, 45%), Mp 149.8–150.4 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.16 (d, *J* = 8.3 Hz, 2H), 7.79 – 7.77 (m, 4H), 6.94 (d, *J* = 1.9 Hz, 2H); ¹³C NMR (101 MHz, CDCl₃) δ 151.07, 143.98, 122.62, 120.22, 119.01, 115.58, 107.70.

6- And 4-fluorobenzofuran (**2u+2u'**)^{19,20}




A mixture of **2u** and **2u'** were afforded as a colorless liquid (78 mg, 0.57 mmol, 57%). Due to the relatively low boiling point of the compounds, some products evaporated away with the chlorobenzene solvent, resulting in low yield. **2u:2u'** = 83:17. **2u** ¹H NMR (400 MHz, CDCl₃) δ 7.60 (d, *J* = 2.3 Hz, 1H), 7.50 (dd, *J* = 8.7, 5.5 Hz, 1H), 7.21 (dd, *J* = 9.6, 2.3 Hz, 1H), 7.02–6.97 (m, 1H), 6.74 (dd, *J* = 2.0, 0.8 Hz, 1H). **2u'** ¹H NMR (400 MHz, CDCl₃) δ 7.59 (d, *J* = 2.2 Hz, 1H), 7.30 (d, *J* = 8.4 Hz, 1H), 7.13–7.05 (m, 1H), 6.94–6.98 (m, 1H), 6.86 (dd, *J* = 2.2, 0.7 Hz, 1H). **2u** ¹³C NMR (101 MHz, CDCl₃) δ 160.99 (d, *J* = 290 Hz), 155.05, 145.59 (d, *J* = 5.0 Hz), 121.35 (d, *J* = 10.1 Hz), 113.80, 111.12 (d, *J* = 24.2 Hz), 106.37, 99.08 (d, *J* = 27.3 Hz).

6- And 4-chlorobenzofuran (**2v+2v'**)¹




A mixture of **2v** and **2v'** were afforded as a colorless liquid (124 mg, 0.81 mmol, 81%); **2v:2v'** = 66:34. ¹H NMR (400 MHz, CDCl₃) δ 7.65 (**2v'**, d, *J* = 2.2 Hz, 1H), 7.61 (**2v**, d, *J* = 2.2 Hz, 1H), 7.52 (**2v**, s, 1H), 7.50 (**2v'**, d, *J* = 8.0 Hz, 2H), 7.44 – 7.40 (**2v'**, m, 1H), 7.25 – 7.20 (**2v**, m, 2H), 6.87 (**2v'**, dd, *J* = 2.2, 0.8 Hz, 1H), 6.75 (**2v**, dd, *J* = 2.1, 0.9 Hz, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 145.71, 145.52, 134.27, 129.81, 128.71, 126.53, 124.95, 123.61, 122.79, 121.76, 112.07, 110.11, 106.57, 105.38.

6- And 4-bromobenzofuran (**2w+2w'**)¹




A mixture of **2w** and **2w'** were afforded as a colorless liquid (169 mg, 0.86 mmol, 86%). **2w:2w'** = 57:47. ¹H NMR (400 MHz,) δ 7.68 (s, 1H), 7.66 (d, *J* = 2.2 Hz, 1H), 7.59 (d, *J* = 2.2 Hz, 1H), 7.47 – 7.45 (m, 1H), 7.45 – 7.43 (m, 1H), 7.39 (d, *J* = 7.7 Hz, 1H), 7.35 (dd, *J* = 8.3, 1.5 Hz, 1H), 7.16 (t, *J* = 8.0 Hz, 1H), 6.81 (**2w'**, dd, *J* = 2.3, 0.9 Hz, 1H), 6.74 (**2w**, dd, *J* = 2.0, 1.0 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 155.34, 154.81, 145.64, 145.47, 129.10, 126.56, 126.26, 125.86, 125.32, 122.21, 117.64, 114.98, 114.35, 110.64, 106.94, 106.64.

6- And 4- (tert-butyl)benzofuran (**2x+2x'**)²¹




A mixture of **2x** and **2x'** was afforded as a colorless liquid (143 mg, 0.82 mmol, 82%). **2x:2x'** = 84:16. ¹H NMR (400 MHz, CDCl₃) δ 7.61 (**2x'**, d, *J* = 2.3 Hz, 1H), 7.58 (**2x**, d, *J* = 2.3 Hz, 1H), 7.51-7.53 (**2x**, m, 2H), 7.37-7.39 (**2x'**, m, 1H), 7.31 (**2x**, dd, *J* = 8.2, 1.4 Hz, 1H), 7.23 (**2x'**, t, *J* = 8.0 Hz, 1H), 7.16 (**2x'**, dd, *J* = 7.5, 1.1 Hz, 1H), 7.01 (**2x'**, dd, *J* = 2.3, 0.9 Hz, 1H), 6.71 (**2x**, dd, *J* = 2.2, 1.0 Hz, 1H), 1.47 (**2x'**, s, 9H), 1.38 (**2x**, s, 9H) ¹³C NMR (101MHz, CDCl₃) δ 155.40, 148.27, 144.77, 143.54, 124.78, 124.00, 120.71, 120.63, 120.46, 118.78, 109.56, 108.11, 107.63, 106.30, 35.02, 31.79, 30.79.

6- And 4-methylbenzofuran (**2y+2y'**)¹




A mixture of **2y** and **2y'** were afforded as a colorless liquid (102 mg, 0.77 mmol, 77%). **2y: 2y'** = 64: 36. ¹H NMR (400 MHz, CDCl₃) δ 7.61 (**2y'**, d, *J* = 2.2 Hz, 1H), 7.55 (**2y**, d, *J* = 2.2 Hz, 1H), 7.47 (**2y**, d, *J* = 7.9 Hz, 1H), 7.38 – 7.29 (m, 2H), 7.19 (**2y'**, t, *J* = 7.8 Hz, 1H), 7.05 (dd, *J* = 13.2, 7.7 Hz, 2H), 6.82 – 6.77 (**2y'**, m, 1H), 6.76 – 6.68 (**2y**, m, 1H), 2.53 (**2y'**, s, 3H), 2.47 (**2y**, s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 155.46, 154.82, 144.43, 134.51, 131.22, 127.29, 124.93, 124.24, 123.05, 120.68, 111.69, 108.89, 106.44, 105.27, 21.74, 18.73.

5-Methylbenzothiophene (**4a**)²²




4a was afforded as a colorless liquid (80 mg, 0.54 mmol, 54%). ¹H NMR (400 MHz, CDCl₃) δ 7.74 (d, *J* = 8.2 Hz, 1H), 7.60 (d, *J* = 0.6 Hz, 1H), 7.38 (d, *J* = 5.4 Hz, 1H), 7.24 (d, *J* = 5.4 Hz, 1H), 7.16 (d, *J* = 8.2 Hz, 1H), 2.46 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 140.07, 137.01, 133.96, 126.51, 126.11, 123.66, 123.62, 122.20, 21.51.

5-Chlorobenzothiophene (**4b**)²³




4b was afforded as a colorless liquid (80 mg, 0.50 mmol, 50%). ¹H NMR (400 MHz, CDCl₃) δ 7.77 (dd, *J* = 6.9, 5.3 Hz, 2H), 7.48 (d, *J* = 5.5 Hz, 1H), 7.29 (dd, *J* = 8.6, 2.0 Hz, 1H), 7.25 (d, *J* = 5.5 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 140.69, 137.81, 130.42, 128.27, 124.65, 123.40, 123.17, 123.11.

7-Methylbenzothiophene (**4c**)²³




4c was afforded as a colorless liquid (90 mg, 0.61 mmol, 61%). ¹H NMR (400 MHz, CDCl₃) δ 7.67 (d, *J* = 7.9 Hz, 1H), 7.41 (d, *J* = 5.4 Hz, 1H), 7.35 (d, *J* = 5.4 Hz, 1H), 7.29 (t, *J* = 7.5 Hz, 1H), 7.14 (d, *J* = 7.2 Hz, 1H), 2.57 (s, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 140.12, 139.54, 132.14, 125.91, 124.70, 124.67, 124.51, 121.35, 20.56.

7-Chlorobenzothiophene (**4d**)²³




4d was afforded as a colorless liquid (123 mg, 0.73 mmol, 73%). ¹H NMR (400 MHz, CDCl₃) δ 7.71 (dd, *J* = 7.3, 1.6 Hz, 1H), 7.48 (d, *J* = 5.4 Hz, 1H), 7.38 – 7.27 (m, 3H); ¹³C NMR (101 MHz, CDCl₃) δ 141.14, 139.20, 128.06, 127.50, 125.51, 124.70, 123.99, 122.14.

7-Bromobenzothiophene (**4e**)³




4e was afforded as a colorless liquid (170 mg, 0.8 mmol, 80%). ¹H NMR (400 MHz, CDCl₃) δ 7.76 (d, J = 8.0 Hz, 1H), 7.51 – 7.46 (m, 2H), 7.42 (d, J = 5.5 Hz, 1H), 7.24 (t, J = 7.8 Hz, 1H); ¹³C NMR (101 MHz, CDCl₃) δ 141.58, 140.51, 127.29, 127.12, 125.57, 124.83, 122.61, 115.94.


¹H NMR spectrum for 1b




¹³C NMR spectrum for 1b




¹H NMR spectrum for 1c




¹³C NMR spectrum for 1c




¹H NMR spectrum for 1d




¹³C NMR spectrum for 1d




¹H NMR spectrum for 1e




¹³C NMR spectrum for 1e




¹H NMR spectrum for 1f




¹³C NMR spectrum for 1f



¹³C NMR spectrum for 1h



HRMS (EI) spectrum for 1h




Elemental Composition Report

Tolerance = 100.0 PPM / DBE: min = -1.5, max = 50.0
Isotope cluster parameters: Separation = 1.0 Abundance = 1.0%


Monoisotopic Mass, Odd and Even Electron Ions
5 formula(e) evaluated with 2 results within limits (up to 50 closest results for each mass)

Minimum:	70.00							
Maximum:	100.00							
Mass	RA	Calc. Mass	mDa	PPM	DBE	Score	Formula	
286.1633	100.00	286.1629	0.4	1.2	7.5	1	C18 H24 N S	


¹H NMR spectrum for **1i**




¹³C NMR spectrum for **1i**



¹H NMR spectrum for 1j



¹³C NMR spectrum for 1j




HRMS (ESI) spectrum for 1j

Xevo G2 Q-TOF/YCA166#


11-19 12 (0.233) Cm (10:16-(2:6+23:27))

19-Mar-2018


Waters
1: TOF MS ES+
1.42e5




¹H NMR spectrum for 1k




¹³C NMR spectrum for 1k




¹H NMR spectrum for 11




¹³C NMR spectrum for 11




¹H NMR spectrum for 1m






¹H NMR spectrum for 1n



¹³C NMR spectrum for 1n



HRMS (ESI) spectrum for 1n


Xevo G2 Q-TOF/YCA166#

19-Mar-2018


Waters

10-27 POS 12 (0.233) Cm (9:15-(2:5+24:40))


1: TOF MS ES+
2.75e4




¹H NMR spectrum for 1o




¹³C NMR spectrum for 1o




¹H NMR spectrum for 1p



¹³C NMR spectrum for 1p



HRMS (EI) spectrum for 1p




Elemental Composition Report

Multiple Mass Analysis: 2 mass(es) processed
Tolerance = 100.0 PPM / DBE: min = -1.5, max = 50.0
Isotope cluster parameters: Separation = 1.0 Abundance = 1.0%


Monoisotopic Mass, Odd and Even Electron Ions
22 formula(e) evaluated with 2 results within limits (up to 50 closest results for each mass)

Minimum:	70.00				-1.5			
Maximum:	100.00		200.0	100.0	50.0			
Mass	RA	Calc. Mass	mDa	PPM	DBE	Score	Formula	
278.0472	100.00	278.0477	-0.5	-1.6	4.0	1	C12 H16 O3 Cl2	

¹H NMR spectrum for 1q




¹³C NMR spectrum for 1q




HRMS (EI) spectrum for 1q


F1




¹H NMR spectrum for 1r




¹³C NMR spectrum for 1r




HRMS (EI) spectrum for 1r




¹H NMR spectrum for 1s




¹³C NMR spectrum for 1s




¹H NMR spectrum for 1t




¹³C NMR spectrum for 1t




¹H NMR spectrum for 1u



¹³C NMR spectrum for 1u



HRMS (EI) spectrum for 1u




Elemental Composition Report

Tolerance = 100.0 PPM / DBE: min = -1.5, max = 50.0
Isotope cluster parameters: Separation = 1.0 Abundance = 1.0%


Monoisotopic Mass, Odd and Even Electron Ions
29 formula(e) evaluated with 10 results within limits (up to 50 closest results for each mass)

Minimum:	70.00							
Maximum:	100.00		200.0	100.0	50.0			
Mass	RA	Calc. Mass	mDa	PPM	DBE	Score	Formula	
228.1164	100.00	228.1162	0.2	1.0	4.0	4	C12 H17 O3 F	


¹H NMR spectrum for 1v




¹³C NMR spectrum for 1v




¹H NMR spectrum for 1w




¹³C NMR spectrum for 1w




¹H NMR spectrum for 1x



¹³C NMR spectrum for 1x



HRMS (EI) spectrum for 1x




Elemental Composition Report

Tolerance = 100.0 PPM / DBE: min = -1.5, max = 50.0
Isotope cluster parameters: Separation = 1.0 Abundance = 1.0%


Monoisotopic Mass, Odd and Even Electron Ions
9 formula(e) evaluated with 3 results within limits (up to 50 closest results for each mass)

Minimum:	70.00				-1.5			
Maximum:	100.00		200.0	100.0	50.0			
Mass	RA	Calc. Mass	mDa	PPM	DBE	Score	Formula	
266.1885	100.00	266.1882	0.3	1.1	4.0	1	C16 H26 O3	


¹H NMR spectrum for 1y




¹³C NMR spectrum for 1y




¹H NMR spectrum for 3a




¹³C NMR spectrum for 3a




¹H NMR spectrum for 3b




¹³C NMR spectrum for 3b




¹H NMR spectrum for 3c




¹³C NMR spectrum for 3c




¹H NMR spectrum for 3d




¹³C NMR spectrum for 3d




¹H NMR spectrum for 3e




¹³C NMR spectrum for 3e




¹H NMR spectrum for 2a




¹³C NMR spectrum for 2a




¹H NMR spectrum for 2b




¹³C NMR spectrum for 2b




¹H NMR spectrum for 2d




¹³C NMR spectrum for 2d




¹H NMR spectrum for 2e




¹³C NMR spectrum for 2e




¹H NMR spectrum for 2f




¹³C NMR spectrum for 2f




HRMS (EI) spectrum for 2f




¹H NMR spectrum for 2g




¹³C NMR spectrum for 2g




¹H NMR spectrum for 2i




¹³C NMR spectrum for 2i



¹H NMR spectrum for 2j



¹³C NMR spectrum for 2j




HRMS (ESI) spectrum for 2j


Xevo G2 Q-TOF/YCA166#
11-19B 11 (0.216) Cm (9:18-2:5)

19-Mar-2018


Waters
1: TOF MS ES+
3.37e4




¹H NMR spectrum for 2k




¹³C NMR spectrum for 2k




¹H NMR spectrum for 2l




¹³C NMR spectrum for 2l




¹H NMR spectrum for 2m




¹³C NMR spectrum for 2m




¹H NMR spectrum for 2n




¹³C NMR spectrum for 2n





¹H NMR spectrum for 2o




¹³C NMR spectrum for 2o




¹H NMR spectrum for 2p




HRMS (EI) spectrum for 2p




¹H NMR spectrum for 2q




¹³C NMR spectrum for 2q




¹H NMR spectrum for 2r




¹³C NMR spectrum for 2r




HRMS (EI) spectrum for 2r




¹H NMR spectrum for 2s




¹³C NMR spectrum for 2s




¹H NMR spectrum for 2t




¹³C NMR spectrum for 2t




¹H NMR spectrum for 2u and 2u'




¹³C NMR spectrum for 2v and 2v'




¹H NMR spectrum for 2w and 2w'




¹³C NMR spectrum for 2w and 2w'




¹H NMR spectrum for 2x and 2x'




¹³C NMR spectrum for 2y and 2y'




¹H NMR spectrum for 4a




¹³C NMR spectrum for 4a




¹H NMR spectrum for 4b




¹³C NMR spectrum for 4b




¹H NMR spectrum for 4c




¹³C NMR spectrum for 4c




¹H NMR spectrum for 4d




¹³C NMR spectrum for 4d




¹H NMR spectrum for 4e




¹³C NMR spectrum for 4e




¹H NMR spectrum for aldehyde intermediate I



¹³C NMR spectrum for aldehyde intermediate I



Infrared absorption spectrum of aldehyde intermediate I



8. REFERENCES

1. N. Sun, P. Huang, Y. Wang, W. Mo, B. Hu, Z. Shen and X. Hu, *Tetrahedron*, 2015, **71**, 4835-4841.
2. C. H. Jin, D. K. Kim, Y. Y. Sheen, C. Y. Park, K. Sreenu Rao, K. Maddeboina and V. B. Subrahmanyam, Patent US 8080568B1.
3. M. Hansen, S. E. Jacobsen, S. Plunkett, G. E. Liebscher, J. D. Mccorvy, H. Bräuner-Osborne and J. L. Kristensen, *Biorg. Med. Chem.*, 2015, **23**, 3933-3937.
4. R. Singh and S. K. Ghosh, *Tetrahedron*, 2010, **66**, 2284-2292.
5. W. A. L. Van Otterlo, G. L. Morgans, L. G. Madeley, S. Kuzvidza, S. S. Moleele, N. Thornton and C. B. De Koning, *Tetrahedron*, 2005, **61**, 7746-7755.
6. H. Yoshimura, K. Kikuchi, S. Hibi, K. Tagami, T. Satoh, T. Yamauchi, A. Ishibahi, K. Tai, T. Hida and A. Naoki Tokuhara, *J. Med. Chem.*, 2000, **43**, 2929-2937.
7. L. Bian, J. Hai, E. Zhu, J. Yu, Y. Liu, J. Zhou, G. Ge and W. Tang, *J. Mater. Chem. A*, 2015, **3**, 1920-1924.
8. S. Li, Z. Yuan, P. Deng, B. Sun and Q. Zhang, *Polym. Chem.*, 2014, **5**, 2561-2566.
9. K. Haw, J. Michael, Greco, N. Michael, Powell, Eugene, Garavilla, D. Lawrence, Maryanoff and E. Bruce, Patent US 20100048513A1.
10. Naidu, B. Narasimhulu, Ueda, Yasutsugu, Matiskella, D. John, Walker, A. Michael, Banville, Jacques, Beaulieu, Francis, Ouellet, Carl, Plamondon and Serge, Patent US 20070111984A1.
11. M. Pawliczek, B. Milde, P. G. Jones and D. B. Werz, *Chem. Euro. J.*, 2015, **21**, 12303-12307.
12. Y. Li and J. Waser, *Beilstein, J. Org. Chem.*, 2013, **9**, 1763-1767.
13. N. Eawin, B. Paul, *J. Catal.* 1969, **15**, 319-328

14. S. Venkatraman, F. Velazquez, S. Gavalas, W. Wu, K. X. Chen, A. G. Nair, F. Bennett, Y. Huang, P. Pinto and Y. Jiang, *Bioorg. Med. Chem.*, 2013, **21**, 2007-2017.
15. Y. Liu, S. K. Park, Y. Xiao and J. Chae, *Org. Biomol. Chem.*, 2014, **12**, 4747-4753.
16. N. Brown and K. R. Buszek, *Tetrahedron Lett.*, 2012, **53**, 4022-4025.
17. H. Kiyota, Y. Shimizu and T. Oritani, *J. Pestic. Sci.*, 2001, **26**, 93-95.
18. M. Nakano, S. Shinamura, Y. Houchin, I. Osaka, E. Miyazaki and K. Takimiya, *Chem. Commun.*, 2012, **48**, 5671-5673.
19. X.Y. Ye, C. L. Morales, Y. Wang, K. A. Rossi, S. E. Malmstrom, M. Abousleiman, L. Sereda, A. Apedo, J. A. Robl, K. J. Miller, J. Krupinski and D. A. Wacker, *Bioorg. Med. Chem. Lett.*, 2014, **24**, 2539-2545.
20. D. Wu, H. Mei, P. Tan, W. Lu, J. Zhu, W. Wang, J. Huang and J. Li, *Tetrahedron Lett.*, 2015, **56**, 4383-4387.
21. P. L. Barker, P. E. Finke and K. R. Thompson, *Synth. Commun.*, 1989, **19**, 257-265.
22. S. C. Lee, H. Liao and R. Magnus, *Chem. Eur. J.* 2018, **24**, 3608-3612.
23. P. D. Clark, A. Kirk and J. G. K. Yee, *J. Org. Chem.*, 1995, **60**, 1936-1938.